Braxia Scientific Provides Update on Proposed Irwin Transaction; Company Retains Strategic Clinical Assets and Ketamine and Psychedelics Clinical IP
Braxia Scientific Provides Update on Proposed Irwin Transaction; Company Retains Strategic Clinical Assets and Ketamine and Psychedelics Clinical IP
Toronto, Ontario--(Newsfile Corp. - March 16, 2023) - Braxia Scientific Corp. (CSE: BRAX) (OTC PINK: BRAXF) (FWB: 4960) ("Braxia", or the "Company"), a medical research and telemedicine company with clinics providing innovative ketamine and psilocybin treatments for depression and related disorders, announces that Irwin Naturals Inc. ("Irwin") has terminated the non-binding amended and restated letter of intent ("LOI") for a business combination between Irwin and Braxia (the "Proposed Transaction"). Full details of the Proposed Transaction were contained in the Company's news release dated January 27, 2023.
安大略省多倫多--(Newsfile Corp.-2023年3月16日)-BraxiaScience Corp.(CSE：BRAX)(場外交易代碼：BRAXF)(FWB：4960)(以下簡稱“本公司”)宣佈，Irwin Naturals Inc.(以下簡稱“Irwin”)已經終止了Irwin和Braxia二家企業合併的非約束性修訂和重述意向書(“意向書”)，該意向書是一家醫療研究和遠端醫療公司，提供創新的氯胺酮和裸蓋菇素治療抑鬱症及相關疾病的藥物。擬議交易的全部細節包含在該公司日期為2023年1月27日的新聞稿中。
"We are disappointed with the decision by Irwin and that we could not complete the transaction," said Dr. Roger McIntyre, CEO of Braxia. "The Braxia team remains well positioned as global leaders in depression and ketamine research, as ranked by Expertscape, with high quality, trusted clinics and a telemedicine platform launched in the United States."
BraxiaCEO羅傑·麥金太爾博士表示：“我們對爾文的決定感到失望，我們無法完成交易。”根據Expertscape的排名，Braxia團隊仍然是抑鬱症和氯胺酮研究領域的全球領先者，擁有高質量、值得信賴的診所和在美國推出的遠端醫療平臺。
Braxia Maintains its Strategic Clinical IP, Telemedicine and Research Infrastructure Assets and Capabilities
Braxia保持其戰略臨床IP、遠端醫療和研究基礎設施的資產和能力
Braxia and its clinical management team remain market leaders in the research and delivery of mental health novel treatments. The Company is pleased to maintain its strategic assets across three important business verticals - including its Clinical Operations in Canada, a US-based telemedicine platform and International Clinical Research Infrastructure.
Braxia及其臨床管理團隊在精神健康新療法的研究和提供方面仍然是市場領先者。該公司很高興維持其在三個重要業務垂直領域的戰略資產，包括其在加拿大的臨床業務、總部設在美國的遠端醫療平臺和國際臨床研究基礎設施。
"Over the last year, we have accomplished several key milestones in mental health research and development. We are moving forward with our current strategy of developing our clinical operations in Canada, currently providing Ketamine and Psilocybin treatments, while building out our strategic and highly scalable telemedicine business with KetaMD, Inc. in the US. We are also actively building our CRO business providing capabilities and research services to pharmaceutical companies looking to quickly develop or co-develop IP in novel therapeutics", concluded Dr. McIntyre.
麥金泰爾博士總結道：“在過去的一年裡，我們在精神健康研究和開發方面取得了幾個關鍵的里程碑。我們正在推進我們目前在加拿大發展臨床業務的戰略，目前提供氯胺酮和裸蓋菇素治療，同時與美國的KetaMD，Inc.建立我們的戰略性和高度可擴展的遠端醫療業務。我們還在積極建立我們的CRO業務，為希望快速開發或共同開發新型療法知識產權的製藥公司提供能力和研究服務。”
The Company remains committed to evaluating a number of potential strategic opportunities to create shareholder value in the mental health industry which continues to evolve and consolidate.
公司仍致力於評估一些潛在的戰略機會，以在不斷發展和鞏固的精神健康行業創造股東價值。
About Braxia Scientific Corp.
布拉夏科學公司簡介
Braxia is a medical research and telemedicine company with clinics that provide innovative ketamine treatments for persons with depression and related disorders. Braxia also launched its U.S. based end-to-end telemedicine platform KetaMD, that utilizes leading technology to provide access to safe, affordable, and potentially life-changing at-home ketamine treatments for people living with depression and related mental health conditions. Through its medical solutions, Braxia aims to reduce the illness burden of brain-based disorders, such as major depressive disorder among others. Braxia is primarily focused on (i) owning and operating multidisciplinary clinics, providing treatments in-person and virtually for mental health disorders, and (ii) research activities related to discovering and commercializing novel drugs and delivery methods. Braxia seeks to develop ketamine and derivatives and other psychedelic products from its IP development platform. Through its wholly owned subsidiary the Canadian Rapid Treatment Center of Excellence Inc., carrying on business as Braxia Health, the Company operates multidisciplinary community-based clinics offering rapid-acting treatments for depression located in Mississauga, Toronto, Kitchener-Waterloo, Ottawa, and Montreal.
Braxia是一家醫學研究和遠端醫療公司，擁有為抑鬱症和相關疾病患者提供創新型氯胺酮治療的診所。Braxia還推出了其在美國的端到端遠端醫療平臺KetaMD，該平臺利用領先的技術為患有抑鬱症和相關精神健康問題的患者提供安全、負擔得起、可能改變生活的家庭氯胺酮治療。通過其醫療解決方案，Braxia旨在減輕以大腦為基礎的疾病的疾病負擔，如嚴重的抑鬱症等。Braxia主要專注於(I)擁有和經營多學科診所，提供面對面和虛擬的精神健康障礙治療，以及(Ii)與發現和商業化新藥和遞送方法有關的研究活動。布拉夏尋求從其知識產權開發平臺開發氯胺酮及其衍生物和其他迷幻產品。通過其全資子公司加拿大卓越快速治療中心，該公司以BraxiaHealth的名義經營業務，在密西索加、多倫多、基奇納-滑鐵盧、渥太華和蒙特利爾經營多學科社區診所，為抑鬱症提供快速有效的治療。
FOR FURTHER INFORMATION PLEASE CONTACT:
欲瞭解更多資訊，請聯繫：
Braxia Scientific Corp.
Tel: 416-762-2138
Email: info@braxiascientific.com
Website:
布拉夏科學公司
電話電話：416-762-2138
電子郵件電子郵件：info@braxiascientific.com
網站：
The CSE has not reviewed and does not accept responsibility for the accuracy or adequacy of this release.
CSE未對本新聞稿的準確性或充分性進行審查，也不承擔任何責任。
Forward-looking Information Cautionary Statement
前瞻性資訊警示聲明
This news release contains forward-looking statements within the meaning of applicable securities laws. All statements that are not historical facts, future estimates, plans, programs, forecasts, projections, objectives, assumptions, expectations, or beliefs of future performance are "forward-looking statements."
本新聞稿包含符合適用證券法的前瞻性陳述。所有不是歷史事實、未來估計、計劃、計劃、預測、預測、目標、假設、預期或對未來業績的信念的陳述都是“前瞻性陳述”。
Forward-looking statements include statements about the intended promise of ketamine-based treatments for depression, the potential for ketamine or other psychedelics to treat other mental health conditions, the ability of telemedicine to address the unmet need for mental health disorders or expand or accelerate the growth of Braxia, the fact that the Proposed Transaction will not be completed, the Company's strategy of developing its clinical operations in Canada while building out its strategic and highly scalable telemedicine business with KetaMD, Inc. in the United States and the build out of Company's CRO business of providing capabilities and research services to pharmaceutical companies. Such forward- looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results, events, or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such risks and uncertainties include, among others, the failure of ketamine, psilocybin and other psychedelics to provide the expected health benefits and unanticipated side effects, dependence on obtaining and maintaining regulatory approvals, including acquiring and renewing federal, provincial, municipal, local or other licenses and engaging in activities that could be later determined to be illegal under domestic or international laws. Ketamine and psilocybin are currently Schedule I and Schedule III controlled substances, respectively, under the Controlled Drugs and Substances Act, S.C. 1996, c. 19 (the "CDSA") and it is a criminal offence to possess such substances under the CDSA without a prescription or a legal exemption. Health Canada has not approved psilocybin as a drug for any indication, however ketamine is a legally permissible medication for the treatment of certain psychological conditions. It is illegal to possess such substances in Canada without a prescription.
前瞻性陳述包括：基於氯胺酮的抑鬱症治療的預期承諾；氯胺酮或其他迷幻劑治療其他精神健康疾病的潛力；遠端醫療解決未得到滿足的精神健康障礙的需求或擴大或加速布拉夏的增長的能力；擬議的交易將無法完成的事實；該公司在加拿大發展其臨床業務的戰略，同時與美國的KetaMD公司建立其戰略和高度可擴展的遠端醫療業務，以及公司向製藥公司提供能力和研究服務的CRO業務的擴大。此類前瞻性表述涉及已知和未知的風險、不確定性和其他因素，可能導致實際結果、事件或發展與此類前瞻性表述明示或暗示的任何未來結果、事件或發展大相徑庭。除其他外，這些風險和不確定性包括氯胺酮、裸蓋菇素和其他迷幻劑未能提供預期的健康益處和意想不到的副作用，依賴於獲得和維持監管批准，包括獲得和續簽聯盟、省、市、地方或其他許可證，以及從事後來根據國內或國際法可能被認定為非法的活動。氯胺酮和裸蓋菇素目前分別是《受控藥物和物質法》(《受控藥物和物質法》，S.C.1996，c.19)規定的附表一和附表三的受控物質，根據《受控藥物和物質法》，在沒有處方或法律豁免的情況下擁有這類物質是刑事犯罪。加拿大衛生部尚未批准裸蓋菇素作為任何適應症的藥物，但氯胺酮是法律允許用於治療某些心理疾病的藥物。在加拿大，在沒有處方的情況下擁有這種物質是違法的。
These factors should be considered carefully, and readers are cautioned not to place undue reliance on such forward-looking statements.
這些因素應仔細考慮，並告誡讀者不要過度依賴此類前瞻性陳述。
Although the Company has attempted to identify important risk factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other risk factors that cause actions, events or results to differ from those anticipated, estimated or intended. Additional information identifying risks and uncertainties that could affect financial results is contained in the Company's filings with Canadian securities regulators, including the Amended and Restated Listing Statement dated April 15, 2021 and its most recent MD&A, which are available at . There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in forward-looking statements.
儘管公司試圖確定可能導致實際行動、事件或結果與前瞻性陳述中描述的大不相同的重要風險因素，但可能存在其他風險因素，導致行動、事件或結果與預期、估計或預期的不同。識別可能影響財務業績的風險和不確定因素的其他資訊包含在公司提交給加拿大證券監管機構的檔案中，包括日期為2021年4月15日的修訂和重新發布的上市聲明以及最新的MD&A，這些檔案可在上查閱。不能保證前瞻性陳述將被證明是準確的，因為實際結果和未來事件可能與前瞻性陳述中預期的大不相同。
To view the source version of this press release, please visit
要查看本新聞稿的源版本，請訪問
譯文內容由第三人軟體翻譯。